PD-L1 Expression for Immunotherapy Agents in Lung Cancer? Vital or "Don't Ask, Don't Tell"?
Article
In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed by a broadened approval for Opdivo (nivolumab) for previously...